Publications
Detailed Information
Development of a severe combined immunodeficiency (SCID) mouse model consisting of highly disseminated human B-Cell leukemia/lymphoma, cure of the tumors by systemic administration of immunotoxin, and development/application of a clonotype-specific polymerase chain reaction-based assay
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yoshida, Minoru | - |
dc.contributor.author | Rybak, Rachel J. | - |
dc.contributor.author | Choi, Youngmin | - |
dc.contributor.author | Greenberg, Steven J. | - |
dc.contributor.author | Barcos, Maurice | - |
dc.contributor.author | Kawata, Akira | - |
dc.contributor.author | Matsuno, Fumihiko | - |
dc.contributor.author | Tsai, Hilda | - |
dc.contributor.author | Seon, Ben K. | - |
dc.date.accessioned | 2023-04-19T07:07:25Z | - |
dc.date.available | 2023-04-19T07:07:25Z | - |
dc.date.created | 2021-04-14 | - |
dc.date.issued | 1997-02 | - |
dc.identifier.citation | Cancer Research, Vol.57 No.4, pp.678-685 | - |
dc.identifier.issn | 0008-5472 | - |
dc.identifier.uri | https://hdl.handle.net/10371/190815 | - |
dc.description.abstract | A new severe combined immunodeficiency (SCID) mouse model consisting of highly disseminated human B-cell leukemia/lymphoma was developed by i.v. inoculation of BALL-1a, an in vivo adapted malignant B-cell line, A 100% transplantability was achieved in nonpreconditioned SCID mice using various BALL-1a doses between 2.5 x 10(4) and 6 x 10(6) cells, Hind-teg paralysis preceded the death of the mice. Utility of the developed tumor model for the therapeutic studies was investigated by i.v. administration of an anti-B-cell monoclonal antibody SN7 (IgG1) and its conjugate with deglycosylated ricin A chain (dgRA), The therapy was initiated 2, 4, or 6 days after tumor inoculation using 4 x 24 mu g of SN7-dgRA or 4 x 20 mu g of SN7; the total dose (96 mu g) of SN7-dgRA corresponded to 14% of the LD(50) dose, SN7-dgRA showed a strong antitumor efficacy in all groups of treated mice, All of the day-2 group mice (n = 7) and six (66.7%) of the day-4 group mice (n = 9) survived healthily for as long as followed (240 days), whereas four (57.1%) of the day-6 group mice (n = 7) survived healthily for as long as followed (200 days), Unconjugated SN7 showed a significant antitumor efficacy but was less effective than SN7-dgRA. A PCR-based assay specific for the clonogenic BALL-1a tumor was developed and applied to determine tumors in various organs of BALL-1a-bearing SCID mice. The assay was highly sensitive in screening for trace quantities of residual tumors in various organs of SCID mice, and it could detect 1 malignant cell/2.5 x 10(5) tissue cells. The PCR-based assay was shown to be much more powerful than the conventional histological analysis in detecting residual tumors. Furthermore, we could estimate quantities of the detected tumors by the PCR-based assay, It is remarkable to find that all examined organs of some of the SN7-dgRA-treated mice were tumor-free as determined by the clonotype-specific PCR-based assay. The present results show the usefulness of the newly developed SCID mouse model, SN7-dgRA, and the clonotype-specific PCR-based molecular assay for the study of therapy of human B-cell leukemia/lymphoma. | - |
dc.language | 영어 | - |
dc.publisher | American Association for Cancer Research | - |
dc.title | Development of a severe combined immunodeficiency (SCID) mouse model consisting of highly disseminated human B-Cell leukemia/lymphoma, cure of the tumors by systemic administration of immunotoxin, and development/application of a clonotype-specific polymerase chain reaction-based assay | - |
dc.type | Article | - |
dc.citation.journaltitle | Cancer Research | - |
dc.identifier.wosid | A1997WH81500023 | - |
dc.identifier.scopusid | 2-s2.0-0031053056 | - |
dc.citation.endpage | 685 | - |
dc.citation.number | 4 | - |
dc.citation.startpage | 678 | - |
dc.citation.volume | 57 | - |
dc.description.isOpenAccess | N | - |
dc.contributor.affiliatedAuthor | Choi, Youngmin | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | RICIN-A-CHAIN | - |
dc.subject.keywordPlus | ACUTE LYMPHOBLASTIC LEUKEMIAS | - |
dc.subject.keywordPlus | MONOCLONAL-ANTIBODIES | - |
dc.subject.keywordPlus | IMMUNOLOGICAL CLASSIFICATION | - |
dc.subject.keywordPlus | ANTITUMOR EFFICACY | - |
dc.subject.keywordPlus | ALPHA-INTERFERON | - |
dc.subject.keywordPlus | ACTIN GENE | - |
dc.subject.keywordPlus | PHASE-I | - |
dc.subject.keywordPlus | T-CELL | - |
dc.subject.keywordPlus | LYMPHOMA | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.